Skip to main content
Premium Trial:

Request an Annual Quote

Solvd Health Gets CE Mark for Opioid Use Disorder Risk Assessment Test

NEW YORK — Solvd Health said on Monday that it has received CE marking for its genetic risk assessment test for opioid use disorder.

According to the Carlsbad, California-based company, the test analyzes a cheek swab sample for 15 genetic variants that have been implicated in the brain's reward pathway and can help guide the use of oral opioids for acute pain.

"Any time prescription opioids are used to manage pain, there is a risk of addiction," Solvd CEO Keri Donaldson said in a statement. "Knowing a patient's risk prior to opioid exposure gives clinicians and patients the data they need to make more informed decisions."

Solvd said the test is currently under review by the US Food and Drug Administration, which granted it a breakthrough device designation in 2018.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.